Drug resistance reversal--are we getting closer? (Q35577444)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

review article

1 reference

title

Drug resistance reversal--are we getting closer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

S B Kaye

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 November 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

2450-2461

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

Multidrug resistance in cancer: role of ATP-dependent transporters

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Role of Intraperitoneal Chemotherapy in the Front-Line Setting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Effect of pegylation on pharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

The dawning era of polymer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Expression of multidrug resistance-associated markers, their relation to quantitative pathologic tumour characteristics and prognosis in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Chemotherapy for metastatic breast cancer-report of a European expert panel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

DNA damage and repair

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

The DNA damage response: putting checkpoints in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

p53 status and the efficacy of cancer therapy in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

p53 and chemosensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Prognostic significance of ras/p21 alterations in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

STI571 (Gleevec) as a paradigm for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

The development and clinical use of trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Translating basic cancer research into new cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Issues and progress with protein kinase inhibitors for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Complexities in the development of cyclin-dependent kinase inhibitor drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Drug inhibition of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Farnesyltransferase inhibitors: promises and realities

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Targeting RAS signalling pathways in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Therapeutic exploitation of the p53 pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Improving cancer therapy by non-genotoxic activation of p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Telomere maintenance as a target for anticancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Telomerase: a target for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Telomeres and telomerases as drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Inhibitors of integrins

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Proteasome inhibition: a novel approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Hsp90 inhibitors as novel cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Androgen receptor signalling: comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3eta

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Hsp90 Regulates Androgen Receptor Hormone Binding Affinityin Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

The Function of Steroid Hormone Receptors Is Inhibited by the hsp90-specific Compound Geldanamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Thymidylate synthase: a critical target for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Phase I Study of an Oral Formulation of ZD9331 Administered Daily for 28 Days

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900619-1

7 January 2021

10.1016/S0959-8049(03)00619-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602131%20AND%20SRC:MED&resulttype=core&format=json